Duffel

Researchers are studying patients with major depressive disorder who may have an immune-related subtype of depression. This subtype affects about 30% of people with depression and is linked to more severe symptoms, lower quality of life, and resistance to current treatments. The trial aims to test two anti-inflammatory drugs, celecoxib and minocycline, as add-on therapies to see if they help improve depression symptoms compared to a placebo. The study uses a stratification approach to identify which patients with inflammation might benefit most from each treatment. This is a Phase 3, randomized, double-blind, placebo-controlled trial designed to compare these therapies directly. Participants will be randomly assigned to receive oral capsules of either celecoxib (200 mg twice daily), minocycline (100 mg twice daily), or a placebo for 12 weeks. Treatment is added to their existing antidepressant medication, which must be stable before starting. The study will monitor patients closely during this 12-week period to assess the effects of these add-on treatments on depression severity. During the study, participants will be assessed for changes in depression symptoms using the Hamilton Depression Rating Scale over 12 weeks. Researchers will also measure remission rates of depression. Participants will undergo baseline evaluations, including confirmation of diagnosis and inflammatory status, and will be monitored for safety and treatment adherence throughout the trial. The total study duration for each participant is 12 weeks of treatment.